Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Research Officer | January 31, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date January 31, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.02 · Expires 2032-01-31 | Direct | 32,319 |
Reported balance
After 2022-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-31 · Grant · Acquired 32,319 · Balance 32,319 F1: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,746 |
Reported balance
After 2022-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-31 · Grant · Acquired 4,746 · Balance 4,746 F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
F3: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2017 Filed Jan 18, 2017 23:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,625 | $40.63 | $66,023.75 |
DisclosureSEC source: 0001209191-17-004302 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,183 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.90 to $41.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,625 | $43.39 | $70,508.75 |
DisclosureSEC source: 0001209191-17-003587 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,558 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.50 to $45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.